KOL Investor Event - SOL-GEL TECHNOLOGIES LTD

Financial Performance:

• No specific Q1/Q4 revenue, profit margins, or cash flow figures were disclosed, as the company remains pre-revenue and focused on drug development.
• The CEO highlighted a "high contribution" per patient due to high pricing potential, suggesting strong future unit economics without needing massive patient volume for profitability.
• The company plans to retain the majority of economics by launching independently in the US rather than licensing, aiming for profitability sooner than capital-intensive peers (e.g., citing Acutis) that required hundreds of millions in burn.
• R&D costs are implied to be significant but controlled, with a low dropout rate (10%) in the Phase 3 trial reducing per-patient statistical costs compared to previous iterations.
• Intellectual property (IP) protection is projected to last until 2045, providing a long commercial moat.

Guidance and Future Outlook:

• Top-line Phase 3 results for SGT 610 (patidigib) are expected next month.
• New Drug Application (NDA) submission is targeted for April, with approval anticipated in Q2 of the following year (approx. 6 months post-submission due to Orphan Drug and Breakthrough Therapy designations).
• Commercial launch is scheduled for early 2028.
• Long-term goals include expanding indications beyond Gorlin syndrome patients to high-frequency BCC patients and potentially pediatric populations (once safety data confirms no impact on growth).
• Management anticipates a "protective effect" that may grow over time, projecting a potential 50% reduction in new BCCs if treatment continues beyond the 12-month study window.

Business Segments and Product Lines:

• Primary Asset: SGT 610 (patidigib), a topical hedgehog pathway inhibitor, is the sole near-term product targeting Gorlin syndrome.
• Mechanism: Blocks the hedgehog signaling pathway, specifically targeting the PTCH1 mutation responsible for 85% of Gorlin cases.
• Clinical Trial Data: Post-hoc analysis of the prior Pelopharm study indicated efficacy in patients regardless of BCC count (2 to 10+), but efficacy was obscured in low-burden patients due to the natural stability of their disease (placebo effect).
• Study Improvements: Current Phase 3 trial mandates PTCH1 mutation status, uses a minimum of 3 facial BCCs (previously 10), and employs dermatoscopes and central review boards to ensure accuracy, resulting in a 10% dropout rate vs. historical norms.
• Future Pipeline: Potential expansion into BCC size reduction (neoadjuvant therapy), treatment of Odontogenic Keratocysts (OKCs), and broader body surface areas beyond the face.

Market and Competitive Landscape:

• Target Market: Conservative estimate of 600,000 eligible patients in the US (from 11,000 diagnosed, adjusted for severity); peak sales projected at 4,000 patients (65% penetration).
• Pricing Strategy: Positioned as a premium topical drug, priced comparable to other expensive topicals but half the cost of oral hedgehog inhibitors (like Erivedge/Vismodegib).
• Competition: Current standard of care includes surgical removal (Mohs, curettage) and oral hedgehog inhibitors, the latter suffering from high discontinuation rates (54%) due to side effects (taste loss, muscle cramps, hair loss).
• Competitive Advantage: SGT 610 offers a non-oral, non-surgical alternative with minimal side effects, addressing the primary unmet need for tolerability and prevention.
• Commercial Reach: US commercialization will be independent with a small team (approx. 20 FTEs) targeting ~200 centers of excellence; international markets (EU/Rest of World) planned for partnership models to navigate pricing controls.

Risks and Challenges:

• Study Design Constraints: The Phase 3 requirement for 10+ BCCs is an enrichment strategy to show statistical significance; there is a risk the FDA or market may initially restrict labeling to this high-burden group, despite data suggesting efficacy in lower burdens.
• Regulatory Uncertainty: While FDA feedback suggests study modifications (like the current trial design) are acceptable, final label indications remain subject to review.
• Adherence: Long-term compliance is critical for a chronic condition; patient retention strategies are vital to maintain efficacy and revenue.
• Geographic Pricing: International pricing is constrained by local regulations, potentially limiting global revenue potential compared to the US market.
• Pediatric Safety: Use in children is currently excluded due to concerns about growth plate impact, requiring gradual safety data accumulation before approval.

Management Commentary and Tone:

• Tone: Highly confident, optimistic, and patient-centric. Management expressed strong conviction in the drug's potential to "revolutionize" treatment.
• Confidence in Data: CEO Maury emphasized that the drug's mechanism is proven and that the current study design corrects previous flaws (dropout rates, patient selection) to ensure success.
• Strategic Clarity: Clearly articulated a "America First" independent commercialization strategy, citing the niche market size and high contribution margins as enablers for a small company to succeed.
• Transparency: Openly discussed the "enrichment" strategy (10 BCCs) as a statistical necessity rather than a limitation of drug efficacy, arguing that waiting for patients to reach 10 lesions is clinically unreasonable.

Analyst Questions and Answers:

• Adoption Speed: KOLs (Dr. Sarin, Dr. Blingsley) predicted rapid adoption ("if you build it, they will come") due to high patient demand and the limitations of current therapies.
• Labeling Expectations: Management expects the FDA to follow precedent, potentially allowing use in patients with fewer than 10 BCCs post-approval, despite the trial's higher threshold, because waiting for disease progression is not clinically sound.
• Genetic Subgroups: Clarification provided that PTCH1+ patients (80-85%) are highly responsive, while SUFU+ patients (5%) may be less responsive due to downstream resistance mechanisms.
• Study Power: Confirmed the 113 enrolled/102 completed patients provide sufficient power (90%) to detect a 40% reduction, potentially more if standard deviation is lower than the original study.
• Baseline BCC Impact: KOLs agreed that higher baseline BCC counts correlate with higher placebo response rates, justifying the enrichment strategy to reveal the drug's true efficacy.

Other Key Points:

• Patient Perspective: Julie Brenizer (GSA) shared powerful personal testimony, noting patients have no current FDA-approved treatments and face 25 days of lost life/year due to treatments. Patients expressed a 94% preference for a preventive drug with no challenging side effects.
• Science of Hedgehog Pathway: Dr. Epstein explained the "interception" concept, where preventing BCC formation early (before they grow) is more effective than treating established tumors, similar to precancerous lesion management.
• Surgeon Perspective: Dr. Blingsley emphasized that "surgical fatigue" is a major barrier for patients; SGT 610 could reduce the frequency and extent of surgeries, preserving tissue and minimizing scarring.
• Market Dynamics: The disease burden is often underestimated; many patients are undiagnosed until adulthood or misdiagnosed due to the diverse appearance of BCCs (e.g., mimicking moles).
• Commercial Pillars: Strategy includes awareness building, direct patient identification, collaboration with the Gorlin Syndrome Alliance for regional centers of excellence, and robust adherence programs.